---
title: Epitope base editing CD45 in hematopoietic cells enables universal blood cancer
  immune therapy
date: '2023-08-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37651540/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230901181251&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: In the absence of cell-surface cancer-specific antigens, immunotherapies
  such as chimeric antigen receptor (CAR) T cells, monoclonal antibodies, or bispecific
  T cell engagers typically target lineage antigens. Currently, such immunotherapies
  are individually designed and tested for each disease. This approach is inefficient
  and limited to a few lineage antigens for which the on-target/off-tumor toxicities
  are clinically tolerated. Here, we sought to develop a universal CAR T cell therapy
  ...
disable_comments: true
---
In the absence of cell-surface cancer-specific antigens, immunotherapies such as chimeric antigen receptor (CAR) T cells, monoclonal antibodies, or bispecific T cell engagers typically target lineage antigens. Currently, such immunotherapies are individually designed and tested for each disease. This approach is inefficient and limited to a few lineage antigens for which the on-target/off-tumor toxicities are clinically tolerated. Here, we sought to develop a universal CAR T cell therapy ...